ATLANTA, GA -- (Marketwire) -- 01/15/13 -- Robert T. McNally, Ph.D., President & CEO of GeoVax Labs (OTCQB: GOVX), along with David A. Dodd, Chairman of the Board, today issued the following update letter to shareholders:
Dear Fellow Shareholders,
Since our last shareholder update letter in May 2012, we have continued the steady progress of the clinical development of HIV/AIDS vaccines for both therapeutic and preventive applications. As we begin a new year, we are pleased to provide you this brief update on recent developments at GeoVax and our plans for 2013 and beyond.
Therapeutic HIV/AIDS Vaccine
As we have noted before, of the 1.2 million Americans infected with HIV, only 30 percent have successfully suppressed their infection using drugs. Thus, there is a need for simpler therapies to control HIV infections.
Preventive HIV/AIDS Vaccine
Although success with a therapeutic program would contribute to improved patient care, prevention still remains the number one objective of national vaccine programs. It is worth repeating that, for the last two decades in this country, the incidence of new HIV infections has remained virtually unchanged at 55,000 new infections annually. The press has heralded stories about the use of oral medication taken on a daily basis as the new means for prevention. What they fail to disclose is the cost and, in some cases, medical side effects associated with this therapy. Human nature, being what it is, tends to be inconsistent in adhering to such a regimen. Throughout recent history, eradication of viral infections has been accomplished through vaccination.
Financing and Corporate Development
We wish to once again thank our shareholders for their long-term and continued support.
Robert T. McNally
President & CEO
David A. Dodd
Chairman of the Board
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from a Phase 1 study supported a Phase 2a trial that was completed in the 3rd quarter of 2012.
GeoVax's 2nd generation preventive vaccine is currently in phase 1 testing and is planned to progress to phase 2 efficacy testing, given safety and immunogenicity are as expected. Overall, the GeoVax vaccine, in various doses and combinations, has been tested in close to 500 humans. GeoVax is also enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.
HIV infection, which can lead to AIDS, is a pandemic that can affect anyone, regardless of race, gender, age, or sexual orientation. 33 million people are currently infected globally; it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, more than a million people in the U.S. have contracted the virus. Every 9 1/2 minutes, someone in the U.S. is infected with HIV. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to function against clade B.
For more Information, please visit www.geovax.com.
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.